NASDAQ$ORIC
ORIC Pharmaceuticals Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
ORIC Pharmaceuticals reported Q4 2024 a net loss of $36.3M, diluted EPS of $-0.51.
For Q4 2024, ORIC Pharmaceuticals reported net loss was $36.3M, diluted EPS was $-0.51. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Net loss $36.3M.
- Diluted EPS $-0.51.
- MD&A highlights operating priorities, liquidity, and sector risks.
Headline financials
Revenue & EPS history
ORIC Pharmaceuticals · Revenue · Quarterly
$0
Forward guidance
Outlook emphasizes clinical milestones, liquidity runway, and operating expense discipline.
Tailwinds
- Pipeline progress and partnership economics.
- Cash supports near-term operating plans.
Headwinds
- Operating losses until commercial scale.
- Financing and trial outcomes affect funding costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.2%
Avg return
Earnings day
+1.1%
Avg return
5 days after
+8.0%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+14.7%
Q2 2023
Best reaction
-29.8%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +14.7% | +14.9% | +5.7% | |
| Q3 2025 | +0.3% | -5.8% | -23.1% | |
| Q2 2025 | -1.0% | -7.9% | +8.9% | |
| Q1 2025 | +8.7% | +25.8% | +98.9% | |
| Q4 2024 | +0.8% | +2.1% | -43.5% | |
| Q3 2024 | -0.3% | -17.5% | -18.2% | |
| Q1 2024 | -1.0% | -7.4% | -5.6% | |
| Q4 2023 | -4.5% | +0.7% | -33.3% | |
| Q3 2023 | -3.2% | -11.9% | +26.4% | |
| Q2 2023 | +14.7% | +13.8% | +17.3% | |
| Q1 2023 | -0.4% | +0.1% | +11.4% | |
| Q4 2022 | +5.3% | +14.8% | +39.5% | |
| Q3 2022 | +2.8% | +17.9% | +35.4% | |
| Q2 2022 | +3.2% | -2.1% | -26.4% | |
| Q1 2022 | -3.4% | -4.4% | +52.0% | |
| Q4 2021 | -29.8% | -33.0% | -42.6% | |
| Q3 2021 | +7.1% | +8.4% | -7.1% | |
| Q2 2021 | +9.4% | +13.6% | +45.2% | |
| Q1 2021 | +2.1% | +6.1% | -17.0% | |
| Q4 2020 | -6.2% | -7.6% | -10.2% | |
| Q3 2020 | +3.8% | +4.4% | +55.6% | |
| Q2 2020 | +12.5% | +12.4% | +7.8% | |
| Q1 2020 | -8.7% | -11.3% | +7.3% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro